Jay Rau
Maple Grove, MN (USA)
Role(s):
VP/SVP/Dept Head
DxNow, Inc
Find More Startups
Startup
Location:
Worcester
Industry:
Other
Year Founded:
2013
Number Employees:
1-10 people
Business Stage:
Growth (not profitable)
Entity Type:
"C" Corporation
Description:
Founded in 2013, DxNow is leveraging exclusively licensed proprietary technologies developed in the Demirci BAMM Labs at Harvard Medical School/Brigham & Women’s Hospital and Stanford University School of Medicine.
Combining novel portable bio-imaging systems with microfluidic-based consumables, our products address applications in male fertility, forensics, renal dialysis, cancer, hematology, infectious disease, and life science research.
Our first products, FERTILE™ and FERTILE PLUS™, are centrifugation-free sperm sorting slides for human reproductive endocrinology applications. CE registered, they are now being sold in Europe. We are also working with key veterinary market opinion leaders to validate utility in animals. The FERTILE and FERTILE PLUS market exceeds $1 Billion.
Providing a method for rapid processing of sexual assault evidence, our Next Generation Differential Extraction (NGDE™) system will enable significant reductions in casework backlogs. More than 840,000 cases annually worldwide involve sexual assault. Evidence processing requires separation of the victim’s cells (epithelial) from the perpetrator’s cells (sperm) and requires time-consuming selective cell lysis, centrifugation and separation into female and male DNA fractions (a process known as differential extraction). Differential extraction has been identified by the USDOJ as a major bottleneck in processing sexual assault samples. Currently, differential extraction involves a labor-intensive 6 to 8 hour process. With our NGDE system, the process will be reduced to under 2 hours and require just 15 minutes of technician time.
With no sample prep required, DxNow's technology can identify and quantify targets ranging in size from eukaryotic cells to molecular analytes (proteins, toxins, drugs, etc.) within a broad dynamic range. Offering performance similar to qRT-PCR, the platform is significantly more sensitive than ELISA. Additionally, there are benefits in cost, speed, logistics, as well as the ability to automate for high throughput applications or configure as a portable, battery-operated system for remote or POC utility. The total market for current and future products exceeds $31 Billion.